As the use of AI spreads through every industry and becomes more of a part of our lives every day, researchers are also ...
Servier today announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) ...
Servier today announced that VORANIGO® (vorasidenib) has been awarded The Galien Foundation's 2025 Prix Galien USA ...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the launch of its ...
Early-stage lung adenocarcinoma alters DNA methylation, mRNA transcription, and protein expression in adjacent tissues, exhibiting either steep changes at the tumor boundaries or shallow changes ...
Fake honey is a global concern. New research offers quick tests to spot cheaper materials mixed into pure honey. Scientists ...
The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...
In two replicate Phase 3 studies, upadacitinib (RINVOQ ® ) achieved the co-primary endpoints of 50% reduction in Total Vitiligo Area Scoring Index (T-VASI 50) from baseline and 75% reduction in Facial ...
Objective: To describe the joint manifestations associated with clonal haematopoiesis and to compare patients with and ...
Objective To investigate the association between peripheral disease activity and pre-eclampsia, gestational hypertension, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback